Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00769145 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
A Phase 1 study of Corneal Neovascularization, sponsored by University of Miami.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00769145 is a Phase 1 study of Corneal Neovascularization that has completed, run by University of Miami. The registered enrollment target is 5 participants, below the 81-participant average among 3 other Corneal Neovascularization trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00769145, a Phase 1 study of Corneal Neovascularization, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation.
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (1)
Florida
- Bascom Palmer Eye Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00769145
The ClinicalTrials.gov registry entry for NCT00769145 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 81-participant average among 3 other Corneal Neovascularization trials with a reported enrollment target (94% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Corneal Neovascularization appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00769145 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00769145 about?
NCT00769145 is a clinical study titled "Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery". The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation.
What is the current status of trial NCT00769145?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2008-10. Estimated completion is 2012-03.
What conditions does trial NCT00769145 study?
This clinical trial studies the following conditions: Corneal Neovascularization.
What interventions are being tested in trial NCT00769145?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00769145?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00769145 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corneal Neovascularization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
COMPLETED · Phase 1
-
Corneal Crosslinking for Treatment of Corneal Neovascularization
RECRUITING · Phase 2
-
Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.